Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
SWOG Cancer Research Network
Bristol-Myers Squibb
National Cancer Institute (NCI)
SWOG Cancer Research Network
Northwestern University
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
Harbin Medical University
University of California, Davis
Indiana University
Immunocore Ltd
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
UNICANCER
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Merus B.V.
Children's Hospital Los Angeles
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Shantou University Medical College
University of Miami
Martini-Klinik am UKE GmbH
M.D. Anderson Cancer Center
Jiangsu Cancer Institute & Hospital
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Institut Curie
Amgen
Shanghai Henlius Biotech
University of Kentucky
Bristol-Myers Squibb
Alligator Bioscience AB
University of California, San Diego
Borstkanker Onderzoek Groep
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Medicine Invention Design, Inc
Groupe Oncologie Radiotherapie Tete et Cou
Cardiff University
Peking Union Medical College Hospital
M.D. Anderson Cancer Center
Medicine Invention Design, Inc
Memorial Sloan Kettering Cancer Center
DEKA Biosciences
Ferring Ventures Limited
Ankara University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The Greater Poland Cancer Centre
Fondazione Policlinico Universitario Agostino Gemelli IRCCS